NNC0090-2746, developed by Novo Nordisk A/S, is positioned as a novel adjunct therapy for Type 2 Diabetes (T2D) patients inadequately controlled with metformin. The dual action on GIP and GLP-1 receptors may provide a competitive edge in a crowded diabetes market, particularly against established therapies such as GLP-1 receptor agonists (e.g., liraglutide). The trial's completion and results could enhance Novo Nordisk's portfolio, potentially leading to a strong market entry if efficacy and safety are demonstrated. The T2D market is projected to grow significantly, driven by increasing prevalence and demand for innovative therapies, which may present lucrative opportunities for NNC0090-2746.